Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mieke Aldenhoven is active.

Publication


Featured researches published by Mieke Aldenhoven.


Biology of Blood and Marrow Transplantation | 2008

The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation

Mieke Aldenhoven; Jaap Jan Boelens; Tom J. de Koning

Hurler syndrome (HS) is a severe inborn error of metabolism causing progressive multi-system morbidity and death in early childhood. At present, stem cell transplantation (SCT) is the only available treatment that can prevent central nervous system disease progression in HS patients. Although SCT has been shown to be effective for several important clinical outcome parameters, the reported clinical outcome after successful SCT is variable among HS patients and there are still some major limitations. This review will focus on the clinical outcome of HS patients after successful SCT, with particular emphasis on the long-term outcome and complications. In addition, factors that are suggested to contribute to the variable outcome are outlined, as well as the limitations of SCT in HS patients.


Blood | 2013

Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

Jaap Jan Boelens; Mieke Aldenhoven; Duncan Purtill; Annalisa Ruggeri; Todd E. DeFor; Robert Wynn; Ed Wraith; Marina Cavazzana-Calvo; Attilio Rovelli; Alain Fischer; Jakub Tolar; Vinod K. Prasad; Maria L. Escolar; Eliane Gluckman; Anne O’Meara; Paul J. Orchard; Paul Veys; Mary Eapen; Joanne Kurtzberg; Vanderson Rocha; Timothy A. Driscoll; Daniel Landi; Paul L. Martin; Kristin Page; Suhag Parikh

We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at day 100 was 25%, and chronic GVHD and 5 years was 16%. Overall survival and event-free survival (EFS) at 5 years were 74% and 63%, respectively. EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelated cord blood (CB) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor. EFS was lower after transplantation in 4/6 matched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007). Full-donor chimerism (P = .039) and normal enzyme levels (P = .007) were higher after CB transplantation (92% and 98%, respectively) compared with the other grafts sources (69% and 59%, respectively). In conclusion, results of allogeneic transplantation for HS are encouraging, with similar EFS rates after MSD, 6/6 matched UCB, 5/6 UCB, and 10/10 matched UD. The use of mismatched UD and 4/6 matched UCB was associated with lower EFS.


Blood | 2015

Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

Mieke Aldenhoven; Robert Wynn; Paul J. Orchard; Anne O'Meara; Paul Veys; Alain Fischer; Vassili Valayannopoulos; Bénédicte Neven; Attilio Rovelli; Vinod K. Prasad; Jakub Tolar; Heather Allewelt; Simon A. Jones; Rossella Parini; Marleen Renard; Victoria Bordon; Nico Wulffraat; Tom J. de Koning; Elsa Shapiro; Joanne Kurtzberg; Jaap Jan Boelens

Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized by multisystem morbidity and death in early childhood. Although hematopoietic cell transplantation (HCT) has been performed in these patients for more than 30 years, large studies on the long-term outcome of patients with MPS-IH after HCT are lacking. The goal of this international study was to identify predictors of the long-term outcome of patients with MPS-IH after successful HCT. Two hundred seventeen patients with MPS-IH successfully engrafted with a median follow-up age of 9.2 years were included in this retrospective analysis. Primary endpoints were neurodevelopmental outcomes and growth. Secondary endpoints included neurologic, orthopedic, cardiac, respiratory, ophthalmologic, audiologic, and endocrinologic outcomes. Considerable residual disease burden was observed in the majority of the transplanted patients with MPS-IH, with high variability between patients. Preservation of cognitive function at HCT and a younger age at transplantation were major predictors for superior cognitive development posttransplant. A normal α-l-iduronidase enzyme level obtained post-HCT was another highly significant predictor for superior long-term outcome in most organ systems. The long-term prognosis of patients with MPS-IH receiving HCT can be improved by reducing the age at HCT through earlier diagnosis, as well as using exclusively noncarrier donors and achieving complete donor chimerism.


Biology of Blood and Marrow Transplantation | 2009

Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome.

Jaap Jan Boelens; Vanderson Rocha; Mieke Aldenhoven; Robert Wynn; Anne O'Meara; Gérard Michel; Irina Ionescu; Suhag Parikh; Vinod K. Prasad; Paul Szabolcs; Maria L. Escolar; Eliane Gluckman; Marina Cavazzana-Calvo; Joanne Kurtzberg

Allogeneic stem cell transplantation (SCT) is considered effective in preventing disease progression in patients with Hurler syndrome (HS). Unrelated umbilical cord blood (UCB) grafts are suggested as an alternative to bone marrow (BM) or peripheral blood stem cells (PBSC). We studied 93 HS patients receiving an UCB graft to analyze risk factors for outcomes. The median time from diagnosis to transplant was 4.6 months, median follow-up was 29 months, and median number of nucleated CB cells infused was 7.6 x 10(7)/kg. Most of the patients received 1 or 2 HLA disparate grafts, and the most frequently used conditioning regimen was cyclophosphamide + busulfan (Bu/Cy). All patients received anti-T cell antibody. At post transplant day +60, the cumulative incidence of neutrophil engraftment was 85%. A younger age at transplant and a higher CD34(+) dose at infusion were favorably associated with engraftment. With the exception of 2 patients, all engrafted patients achieved full and sustained donor chimerism. The 3-year event-free survival (EFS) and 3-year overall survival (OS) rates were 70% and 77%, respectively. In a multivariate analyses, use of Bu/Cy and a shorter interval from diagnosis to transplant were predictors for improved EFS rate (82% for patients transplanted within 4.6 months after diagnosis compared to 57% for the rest). Improved outcomes from early transplantation and immediate availability of CB unit lead us to conclude that CB transplantation is a beneficial option, which should be considered expediently for children with HS.


Annals of the Rheumatic Diseases | 2009

Musculoskeletal manifestations of lysosomal storage disorders

Mieke Aldenhoven; Ralph J. B. Sakkers; J.J. Boelens; T J de Koning; Nico Wulffraat

Lysosomal storage disorders (LSDs), a heterogeneous group of inborn metabolic disorders, are far more common than most doctors presume. Although patients with a severe LSD subtype are often readily diagnosed, the more attenuated subtypes are frequently missed or diagnosis is significantly delayed. The presenting manifestations often involve the bones and/or joints and therefore these patients are frequently under specialist care by (paediatric) rheumatologists, receiving inadequate treatment. Since effective disease-specific treatments, including enzyme replacement therapy and stem cell transplantation, have become available for certain LSDs and timely initiation of these treatments is necessary to prevent the development of severe, disabling and irreversible manifestations, early diagnosis has become essential. The challenge is to raise awareness for better recognition of the presenting signs and symptoms of LSDs by all doctors who may encounter these patients, including rheumatologists.


Cytotherapy | 2015

Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions

Mieke Aldenhoven; Joanne Kurtzberg

Initially used as an alternative hematopoietic stem cell source for patients without a human leukocyte antigen-matched bone marrow or peripheral blood stem cell donor, unrelated cord blood (UCB) is now the preferred donor source when hematopoietic stem cell transplantation (HSCT) is used to treat patients with lysosomal storage disorders (LSD). Without transplantation, these patients have serious progressive multi-system deterioration and premature death. UCB transplantation favorably alters the natural history of these diseases and prolongs survival. It primarily works through cellular enzyme replacement by healthy engrafted donor cells providing a continuous endogenous supply of enzyme throughout the body and, thorough engraftment of donor-derived microgial cells, in the central nervous system. HSCT in LSD, the majority performed in patients with mucopolysaccharidoses and leukodystrophies, is associated with remarkably high rates of engraftment and survival. Importantly, recipients of UCB, as compared with other donor sources, more often achieve full-donor chimerism and normalization of enzyme levels, which has been associated with superior long-term clinical prognosis. Additionally, UCB units are readily available, reducing time to transplantation and thereby providing access to transplant at young ages, another highly important predictor for long-term neuro-developmental function. For these reasons, UCB grafts are nowadays considered to be the optimal graft source for HSCT in patients with LSD.


Biology of Blood and Marrow Transplantation | 2010

Dried Blood Spot Analysis: An Easy and Reliable Tool to Monitor the Biochemical Effect of Hematopoietic Stem Cell Transplantation in Hurler Syndrome Patients

Mieke Aldenhoven; Tom J. de Koning; Frans W. Verheijen; Berthil H.C.M.T. Prinsen; Frits A. Wijburg; Ans T. van der Ploeg; Monique G.M. de Sain-van der Velden; Jaap-Jan Boelens

Hurler syndrome (HS), the most severe phenotype in the spectrum of mucopolysaccharidosis type I, is caused by a deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA). At present, hematopoietic stem cell transplantation (HSCT) is the only treatment able to prevent disease progression in the central nervous system, and therefore considered the treatment of choice in HS patients. Because IDUA enzyme activities after HSCT have been suggested to influence the prognosis of HS patients, monitoring these activities after HSCT remains highly important. The use of dried blood spots (DBS) for enzyme analysis can be a useful alternative to the conventional leukocyte assay. Importantly, this method allows for convenient worldwide shipment, and can therefore be applied to monitor patients from larger areas of the world, or during large-scale international studies. Furthermore, this method requires only a minimal amount of blood. From 13 HS patients receiving HSCT, 36 paired whole blood and DBS samples were analyzed to assess leukocyte and DBS IDUA activities, respectively. To correct for potential interfering factors, simultaneous assay of the alpha-Galactosidase-A (AGA) activity was performed in the DBS samples and an IDUA/AGA ratio was calculated. A strong linear correlation was demonstrated between the DBS IDUA/AGA ratio and the leukocyte IDUA activity (r(2) = .875, P < .001). This correlation was applicable to all enzyme activities, including the activities measured early after HSCT as well as heterozygous activities because of mixed chimerism or the use of a carrier donor. These results demonstrate that the DBS method is reliable to monitor the biochemical effect of HSCT in HS patients.


Archive | 2013

Leukodystrophies and Lysosomal Storage Disorders

Maria L. Escolar; Mieke Aldenhoven

The leukodystrophies are a group of inherited metabolic disorders in which there is abnormal development or progressive degeneration of the myelin sheath, the fatty covering that acts as an insulator around nerve fibers. Each of the leukodystrophies is the result of a defect in the gene that controls the production or metabolism of one (and only one) of the many component molecules of myelin. The word leukodystrophy comes from the Greek roots leuko, white, dys, lack of, and troph, growth. Specific leukodystrophies include metachromatic leukodystrophy, Krabbe disease, adrenoleukodystrophy, Pelizaeus–Merzbacher disease, Canavan disease, Alexander disease, Refsum disease, cerebrotendinous xanthomatosis, and childhood ataxia with central nervous system hypomyelination (also known as vanishing white matter disease).


Blood Advances | 2017

Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation

Mieke Aldenhoven; Brigitte T.A. van den Broek; Robert Wynn; Anne O’Meara; Paul Veys; Attilio Rovelli; Simon A. Jones; Rossella Parini; Peter M. van Hasselt; Marleen Renard; Victoria Bordon; Tom J. de Koning; Jaap Jan Boelens

Hurler syndrome (HS) is a lysosomal storage disease characterized by multisystem morbidity and death in early childhood. Hematopoietic stem cell transplantation (HSCT) results in long-term survival, although with significant residual disease burden. How this residual disease affects the health-related quality of life is unknown. Therefore, we conducted a multicenter cohort study on functional and psychosocial health and compared the outcomes to normative data using the Child Health Questionnaire and Pediatric Outcomes Data Collection Instrument. Perception of care was evaluated by the Measure of Processes of Care questionnaire. Sixty-three HS patients receiving HSCT with at least 3 years of follow-up after HSCT were included. The influence of potential predictors was analyzed using linear regression analysis, and correlation analysis was performed using Spearman rank correlation. Functional health of transplanted HS patients was significantly diminished compared with normative data (median physical summary z score, -2.4 [range, -3.5 to -1.6]; median global functioning z score, -3.2 [range, -4.8 to -1.8]). Psychosocial health was comparable or only slightly reduced compared with healthy peers (median psychosocial summary z score, 0.15 [range, -0.7 to 0.8]). A higher obtained lysosomal enzyme level post-HSCT predicted for superior functional health. Overall, parents were satisfied with the care received. Functional health of transplanted HS patients appeared significantly more affected than psychosocial health. To improve functional health, the use of only noncarrier donors and striving to achieve full-donor chimerism, both resulting in higher enzyme levels, is advised. Assessing the health-related quality of life could play an important role in evaluating outcomes of HS patients receiving novel (cell) therapies, including autologous gene-transduced HSCT.


Tijdschrift Voor Kindergeneeskunde | 2010

Presenterende symptomen bij het syndroom van Hurler

C. M. L. Touw; Mieke Aldenhoven; P.M. van Hasselt; Frits A. Wijburg; Q.G.A. Teunissen; A.T. van der Ploeg; M. F. Mulder; J.J. Boelens; T. J. de Koning

SamenvattingDe mucopolysacharidosen (MPS) zijn een groep van erfelijke stofwisselingsziekten die gekenmerkt worden door deficiënties van lysosomale enzymen. Een tekort van deze enzymen resulteert in een progressieve stapeling van onvolledig afgebroken koolhydraatstructuren ofwel glycosaminoglycanen (GAG’s) in diverse organen, wat leidt tot een progressief ziektebeloop met uiteindelijk een multiorgaanziekte.1SummaryIn this clinical case, the importance of early detection of Hurler syndrome for outcomes of stem cell transplantation in this patient population is illustrated. Nowadays, children with Hurler syndrome can be treated with stem cell transplantation, but the results largely depend on the moment of treatment. If the procedure is initiated in an early stage of disease, better results can be obtained. Therefore, early recognition of the disease is essential. In this study, the presenting symptoms of fifteen Dutch patients were studied. The median age of diagnosis was 10 months, but by timely recognition of typical facial features, macrocephaly, hepatosplenomegaly, and kyphosis all patients might have been diagnosed four months earlier on average.

Collaboration


Dive into the Mieke Aldenhoven's collaboration.

Top Co-Authors

Avatar

Robert Wynn

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Veys

Great Ormond Street Hospital

View shared research outputs
Top Co-Authors

Avatar

Anne O'Meara

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom J. de Koning

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Simon A. Jones

Central Manchester University Hospitals NHS Foundation Trust

View shared research outputs
Researchain Logo
Decentralizing Knowledge